Marek’s Disease Vaccine: How It Works and Protects Chickens

Marek’s disease vaccines protect chickens by priming the immune system to fight a herpesvirus that would otherwise cause paralysis, wasting, and lethal tumors. The vaccine does not kill the virus or stop it from spreading between birds. Instead, it trains immune cells to suppress viral replication and prevent the transformation of healthy cells into cancer. This makes Marek’s vaccination unusual among livestock vaccines and raises practical questions about how it actually works, why it sometimes fails, and what it means for modern poultry production.

What Marek’s Disease Does to Chickens

Marek’s disease virus (MDV) is an alphaherpesvirus that infects chickens and causes a range of problems, the most devastating being multiple lymphomas that grow as solid tumors in organs and muscles.¹ The infection unfolds in three stages. First, the virus enters the bird through inhaled dust and undergoes an initial burst of replication, spreading to immune organs. It then goes latent, hiding primarily inside a specific type of white blood cell called CD4+ T cells. In the final stage, some of those infected T cells transform into cancerous cells, and tumors begin growing throughout the body.²

Neurological signs like leg paralysis are common, and chronic wasting can kill birds slowly even before tumors become visible. The virus also suppresses the immune system broadly. Infected chickens show shrinkage of the thymus and bursa (key immune organs), drops in circulating immune cells, and weakened antibody responses to other diseases. That immunosuppression makes birds far more vulnerable to secondary infections like pathogenic E. coli.³ Recent research has linked this immune suppression to the virus activating a type of regulatory T cell that dampens the bird’s immune defenses during the transformation phase of infection.⁴

How the Virus Spreads

MDV spreads through something deceptively ordinary: dust. Infected chickens shed the virus from feather follicle cells, producing contaminated dander that becomes airborne. Other chickens inhale the dust, and the cycle begins again. Virus particles can appear in dander as early as about a week after infection, and the bird begins actively spreading infectious material to flockmates around two weeks after initial exposure.⁵

This airborne route makes Marek’s disease extremely contagious. Dust collected from poultry houses has been shown to remain infectious for about four weeks at room temperature, meaning a contaminated barn can infect new birds long after the original sick flock has been removed.⁶ Virtually every commercial chicken flock encounters the virus at some point. This environmental persistence is a major reason vaccination became essential rather than optional.

A Vaccine Born from Near-Disaster

In the 1960s, Marek’s disease was threatening to cripple the global poultry industry. Mortality rates in some flocks were catastrophic, and no treatment existed. Once researchers identified the herpesvirus responsible, they moved quickly to develop vaccines. The result was historically significant: Marek’s disease vaccination became the first successful use of a vaccine to prevent a naturally occurring cancer in any species.⁷

Three main vaccine types emerged over the decades, each based on a different serotype of the virus. Herpesvirus of turkeys (HVT) was the first widely used vaccine strain. It is a naturally non-pathogenic relative of MDV that cross-protects chickens. SB-1 is a naturally avirulent chicken herpesvirus from a different serotype. And Rispens CVI988, an attenuated version of the actual pathogenic virus, is generally considered the most protective single strain available today. All three integrate into the chicken’s genome after vaccination, a behavior they share with pathogenic strains, though the vaccine strains lack the genetic features that drive tumor formation.⁸

How the Immune Protection Actually Works

The mechanics of Marek’s disease vaccine protection are not as straightforward as you might expect. The vaccine does not simply generate antibodies that neutralize the virus on contact. Instead, the critical protection against tumors appears to rely on a broader immune priming that keeps the virus from completing its transformation program inside the bird’s cells.

A key experiment using the CVI988 vaccine shed light on the different arms of immunity at work. Researchers vaccinated chickens and then selectively removed either their CD4+ or CD8+ T cells before exposing them to virulent MDV. The surprising result: birds missing either T-cell subset were still protected from tumors. But birds lacking CD8+ T cells had much higher virus levels in their CD4+ T cells during the early latent phase. This means CD8+ T cells are essential for controlling viral replication directly, but the anti-tumor effect of the vaccine is maintained through other immune pathways even when those virus-killing cells are absent.⁹

In practical terms, this means the vaccine works on two fronts simultaneously. It reduces the total amount of virus circulating inside the bird, making it harder for enough infected cells to reach the transformation stage. And it activates anti-tumor defenses that can catch and eliminate cells that do start turning cancerous. Both layers matter, and losing one does not necessarily mean losing all protection.

Why the Vaccine Does Not Stop the Virus from Spreading

Here is the part that surprises most people: vaccinated chickens can still become infected with Marek’s disease virus, and they still shed it to other birds. The vaccine prevents the clinical disease (paralysis, tumors, death) but does not create what immunologists call “sterile immunity,” where the pathogen is blocked entirely.¹⁰ This characteristic is sometimes described as a “leaky” vaccine, a term that applies to many livestock and even some human vaccines that block symptoms without fully preventing infection or onward transmission.¹¹

This has a counterintuitive consequence. Because vaccinated birds survive infection with virulent strains and continue shedding virus, those virulent strains keep circulating in the environment. In an unvaccinated flock, the most lethal virus strains would tend to kill their hosts quickly, limiting their own spread. In a vaccinated flock, even very virulent strains get transmitted because the vaccinated host lives long enough to shed them. Over time, this has contributed to the emergence of increasingly virulent pathotypes of MDV. Field viruses in vaccinated poultry populations now show substantial genetic divergence from vaccine strains, sharing only about 82-83% homology with CVI988 in the key oncogene region.¹²

This virulence escalation is why the poultry industry has had to upgrade vaccines over the decades. The original HVT vaccine worked well against the strains circulating in the 1970s but became insufficient as more virulent strains emerged. The industry moved to bivalent combinations (HVT plus SB-1) and eventually to CVI988/Rispens, which remains the gold standard today. Whether even CVI988 will hold up indefinitely against continuing viral evolution is an open question that researchers are watching closely.

Getting the Vaccine into Every Bird

Because Marek’s disease virus is so ubiquitous and chicks can encounter it within days of hatching, vaccination timing is critical. Two delivery methods dominate commercial production.

Subcutaneous injection at hatch was the traditional approach. Workers at the hatchery vaccinate each chick individually, usually in the back of the neck, within hours of hatching. This method is effective but labor-intensive and introduces variability depending on injection technique.

In ovo vaccination, where the vaccine is injected directly into the developing embryo at around 18 days of incubation, has become the preferred method for large-scale broiler production. Automated machines can vaccinate tens of thousands of eggs per hour. However, precise placement matters. Vaccine deposited inside the embryo (intra-embryonically) produces faster development of post-vaccinal immune responses compared to vaccine deposited outside the embryo in the surrounding fluid, which results in a delayed immune response.¹³ Calibrating the injection machines properly is therefore essential to making sure birds are protected before they encounter field virus.

The Cold Chain Problem

Most Marek’s disease vaccines are cell-associated, meaning the vaccine virus is frozen inside living cells rather than being stored as a freeze-dried powder. The most widely used formulation, CVI988, is stored in liquid nitrogen at around minus 196°C. If the vaccine warms up or is thawed and diluted incorrectly, the living cells die and the vaccine loses potency.¹⁴

This is a genuinely difficult logistical challenge, especially in tropical countries or rural operations where maintaining an unbroken liquid nitrogen cold chain from manufacturer to hatchery is expensive and error-prone. Vaccine failures in the field are sometimes blamed on virulent new strains when the real cause is improper handling. The vaccine was dead before it ever reached the bird. Cell-free vaccine formulations exist and are easier to store, but they tend to be less effective per dose, particularly in chicks that have maternal antibodies.

Why Maternal Antibodies Complicate Things

Hens that have been vaccinated or previously infected pass antibodies to their chicks through the egg. These maternal antibodies protect the chick during its first days of life, but they also interfere with vaccine viruses. The antibodies can neutralize the vaccine strain before it has a chance to replicate and prime the chick’s own immune system.

The degree of interference depends on the vaccine format. Cell-associated vaccines, where the virus is sheltered inside living cells, are partially protected from circulating antibodies. Cell-free vaccines, where the virus is exposed directly to the chick’s bloodstream, are much more vulnerable to maternal antibody neutralization. In chicks with maternal antibodies, cell-free vaccines required 15 to 80 times the dose of cell-associated vaccines to achieve the same level of protection.¹⁵

Trivalent vaccines, combining HVT, SB-1, and CVI988, offer one solution to this problem. Even when chicks carry maternal antibodies against all three serotypes, the trivalent combination remains highly effective, significantly outperforming any single-strain vaccine. The different serotypes appear to help each other overcome antibody interference through mechanisms that are not fully understood but produce a synergistic effect.¹⁶

HVT as a Platform for Multi-Disease Vaccines

One of the more elegant developments in poultry vaccination has been repurposing the HVT vaccine strain as a delivery vehicle for antigens from other diseases. Because HVT replicates persistently in the chicken, it can carry foreign genes and express them over time, generating long-lasting immunity against a second pathogen alongside Marek’s disease protection. HVT is now widely used as a recombinant vector for expressing protective antigens from multiple avian pathogens.¹⁷

Recombinant HVT vaccines have been developed against Newcastle disease, infectious bursal disease, and avian influenza, among others. The concept follows what one research team described as a “one stone, two birds” principle: a single vaccination event at the hatchery protects against Marek’s disease and one or more additional threats simultaneously.¹⁸ Recent work has pushed this even further, creating multivalent HVT constructs carrying antigens for both highly pathogenic avian influenza and either infectious bursal disease or Newcastle disease. These triple-target vaccines provided 90 to 100% clinical protection against multiple divergent strains of highly pathogenic avian influenza while maintaining full protection against the co-targeted disease.¹⁹

For poultry producers, this is a practical and economic win. Fewer injections mean less handling stress, lower labor costs, and reduced risk of missing a vaccination. The persistent replication of HVT also means the immune stimulus continues over the bird’s lifetime rather than waning after a few weeks.

Telling Vaccine Virus Apart from Field Virus

When a vaccinated flock starts showing signs of Marek’s disease, the first diagnostic question is whether the vaccine failed or whether the birds were never properly vaccinated. Since CVI988/Rispens is itself a serotype 1 MDV strain, distinguishing it from wild-type pathogenic virus in a laboratory sample is not trivial. Researchers have developed real-time PCR assays that exploit consistent single-nucleotide differences between CVI988 and virulent field strains in genes like pp38 and meq.²⁰ ²¹

These assays can quantify both viruses simultaneously in a single sample, which is useful for figuring out whether a vaccinated bird is carrying mostly vaccine virus (suggesting the vaccine took but the field virus overwhelmed it) or mostly field virus (suggesting poor vaccine uptake). This kind of diagnostic precision matters for outbreak investigations and for monitoring whether current vaccine strains are keeping pace with evolving field strains.

Genetics and Why Some Chickens Resist Better Than Others

Vaccination is the frontline defense, but genetics play a surprisingly large role in determining how well any individual bird handles Marek’s disease virus. The major histocompatibility complex (MHC) in chickens, known as the B complex, is one of the strongest genetic determinants of resistance or susceptibility. Chickens carrying certain MHC haplotypes develop tumors at far lower rates than others.

In White Leghorn breeding studies, birds homozygous for the B21 haplotype showed roughly 24 to 32% mortality after challenge, while those homozygous for B19 suffered around 68% mortality.²² More recent work in a common commercial line confirmed that B15 homozygotes had the lowest tumor incidence, while B21 homozygotes had the fewest organs with tumors among birds that did develop disease.²³

One finding that overturned earlier assumptions is that resistance is not simply inherited as a dominant trait. Instead, the B19 haplotype appears to confer dominant susceptibility, meaning even one copy of B19 tends to make the bird vulnerable. This has implications for breeding programs. Selecting against the most susceptible haplotypes can meaningfully reduce Marek’s disease losses in a flock, and combining genetic resistance with vaccination produces better outcomes than either strategy alone. Industry reviews continue to emphasize that combining vaccination with genetic selection and strict biosecurity is the most effective approach to controlling losses.²⁴

Marek’s Disease as a Cancer Research Model

Beyond its agricultural importance, Marek’s disease occupies a unique position in biomedical science. It was one of the first systems where researchers could study every stage of a virus-induced cancer in a natural host, from initial infection through latency to full tumor development. Among the viral genes driving this process, the protein Meq stands out as the key transforming agent, directly causing the cancerous conversion of infected cells. Another viral protein, vTR (the virus’s version of telomerase), helps maintain cells in their transformed state once Meq has initiated the change.¹

The fact that a vaccine could prevent this cancer made Marek’s disease a proof of concept that still influences thinking about human cancer-prevention vaccines. The parallels are imperfect. Human papillomavirus vaccines, for instance, do aim to prevent virus-driven cancers, but they work by preventing the initial infection rather than by controlling an infection the host already carries. Marek’s vaccines do something harder and messier: they let the virus in but prevent its worst consequences. That messiness is exactly what makes the system so informative for understanding immune surveillance of cancer and the arms race between persistent viruses and their hosts.